Discontinued — last reported Q4 '25
Year-over-year, this metric declined by 100.0%, from $11.20M to $0.00. Over 4 years (FY 2021 to FY 2025), Acquisitions shows a downward trend with a -13.7% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
cf_acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $63.10M | $1.50M | $0.00 | $0.00 | $0.00 | $30.80M | $0.00 | $0.00 | $0.00 | $0.00 | $5.70M | $0.00 | $241.30M | $28.50M | $11.20M | $30.40M | $0.00 | $0.00 | $0.00 |
| QoQ Change | — | — | -97.6% | -100.0% | — | — | — | -100.0% | — | — | — | — | -100.0% | — | -88.2% | -60.7% | +171.4% | -100.0% | — | — |
| YoY Change | — | — | — | — | — | -100.0% | >999% | — | — | — | -100.0% | — | — | — | — | +96.5% | — | -100.0% | -100.0% | -100.0% |